Targeting the B-cell maturation antigen protein has so far proved successful in treatment of relapsed or refractory multiple myeloma, dramatically increasing response rates and extending the time until disease progression.
More years of follow-up are needed to determine the durability of these therapies and whether they provide a functional cure for a proportion of patients, but researchers are not idly waiting to find out.
Instead, they have moved on to the next challenge: finding new treatment targets to help those whose disease has progressed despite the use of BCMA-directed therapy.
